Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
$3.23+0.62%
报价 2026-11-06
市值
$176.9M
EV
$108.3M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -90.1%
$2.74$32.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| UPBUpstream Bio, Inc. | $176.9M | +0.6% | -22.2% | 98.5% | – | – | – | |
| SYRESpyre Therapeutics, Inc. | $9.59B | +7.5% | 0.0% | 0% | – | – | – | |
| RLAYRelay Therapeutics, Inc. | $4.08B | +9.4% | -14.8% | 89.7% | – | – | – | |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.7B | +6.8% | -99.9% | 0% | – | – | – | |
| PHVSPharvaris N.V. | $2.4B | +5.7% | – | 0% | – | – | – | |
| ZBIOZenas BioPharma, Inc. | $1.84B | +9.0% | -47.8% | 0% | – | – | – | |
| NVAXNovavax, Inc. | $1.78B | +10.2% | -61.5% | 77.3% | – | – | – | |
| NTLAIntellia Therapeutics, Inc. | $1.59B | +2.3% | +5.3% | -46.5% | – | – | – | |
| SNDXSyndax Pharmaceuticals, Inc. | $858.9M | +1.8% | +107.0% | 96% | – | – | – | |
| 同行中位数 | – | – | -14.8% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。